This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (1) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kahn, J. Search for Related Content Social Bookmarking                   What's this?

Exploiting Race in Drug Development

BiDil's Interim Model of Pharmacogenomics

Hamline University School of Law, 1536 Hewitt Avenue, St Paul, MN 554104-1237, USA, jkahn01{at}hamline.edu

This paper explores events surrounding the US Food and Drug Administration's formal approval of the heart failure drug BiDil in 2005. BiDil is the first drug ever to be approved with a race-specific indication, in this case to treat heart failure in `self-identified black patients'. BiDil has been cast by many as a step toward the promised land of individualized pharmacogenomic therapies. This paper argues, however, that when examined in context, the approval of BiDil emerges as a new model of how a pharmaceutical company may exploit race in the marketplace by literally capitalizing on the racial identity of minority populations and leveraging the disproportionate risk of adverse health outcomes they suffer into a cheaper, more efficient way to gain the US Food and Drug Administration's approval for drugs. Discussions of BiDil in both popular media and professional journals have repeatedly elided the difference between pharmacogenomic and race-based medicine. In fact, broad-based true pharmacogenomic therapies remain years—perhaps decades—in the future. The story of BiDil's development elucidates an alternative model to developing tailored therapies that promises to fill in the gap between the promise and reality of pharmacogenomic medicine. It is a model that exploits race to gain regulatory and commercial advantage, while ignoring its power to promote a regeneticization of racial categories in society at large.

Key Words: discrimination • ethnicity • FDA • genetics • intellectual property • patents • pharmacogenomics • race • regulation • statistics

Social Studies of Science, Vol. 38, No. 5, 737-758 (2008)
DOI: 10.1177/0306312708091928


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. H. Fujimura, T. Duster, and R. Rajagopalan Race, genetics, and disease: questions of evidence, matters of consequence. Social Studies of Science, October 1, 2008; 38(5): 643 - 656. [Abstract] [PDF]